Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Haloperidol versus placebo for schizophrenia

This is not the most recent version

view the current version 15 November 2013

Information

DOI:
https://doi.org/10.1002/14651858.CD003082.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 18 October 2006see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:

  1. Cochrane Schizophrenia Group

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Claire B Irving

    Correspondence to: Cochrane Schizophrenia Group, The University of Nottingham, Nottingham, UK

    [email protected]

    [email protected]

  • Clive E Adams

    Cochrane Schizophrenia Group, The University of Nottingham, Nottingham, UK

  • Stephen Lawrie

    Department of Psychiatry, University of Edinburgh, Edinburgh, UK

Contributions of authors

Claire Joy ‐ selection of trials, data extraction, writing review.

Clive Adams ‐ 10% check of trials, writing review

Steve Laurie ‐ selection of trials, 10% data extraction check, writing review

Sources of support

Internal sources

  • Cochrane Schizophrenia Group General Fund, UK.

  • University of Oxford Department of Psychiatry, UK.

External sources

  • NHS Executive Anglia and Oxford R&D Directorate, UK.

Declarations of interest

Claire Joy ‐ None.

Clive Adams ‐ has attended and presented at functions sponsored by Janssen‐Cilag and Eli Lilly. These companies have provided travel, accommodation and speaker expenses but no funds have been paid directly to CEA. Payments related to participation in meetings have been paid to an account to support schizophrenia research. The Cochrane Schizophrenia Group has multiple, and hopefully, balancing, competing interests. Potential conflicts of interest of the Group and individuals are described on http://cebmh.warne.ox.ac.uk/csg/ and sources and quantities of all funding, listed.

Steve Lawrie ‐ has been paid for speaking about critical appraisal by employees of the manufacturers of olanzapine, quetiapine, risperidone, and ziprasidone, and has been paid to speak about the management of schizophrenia by employees of the manufacturers of amisulpiride, olanzapine, risperidone, and clozapine. AM and ZN declare that they have no competing interests.

Acknowledgements

The reviewers would like to thank the funders (NHS R&D, UK) who had the vision to support this important review. Dr Jo Wood, then of Janssen‐Cilag Limited, UK, was also generous of her time and supplied a stream of rare reports of trials. We would also like to thank those who have provided editorial input to this review.

Version history

Published

Title

Stage

Authors

Version

2013 Nov 15

Haloperidol versus placebo for schizophrenia

Review

Clive E Adams, Hanna Bergman, Claire B Irving, Stephen Lawrie

https://doi.org/10.1002/14651858.CD003082.pub3

2006 Oct 18

Haloperidol versus placebo for schizophrenia

Review

Claire B Irving, Clive E Adams, Stephen Lawrie

https://doi.org/10.1002/14651858.CD003082.pub2

2001 Apr 23

Haloperidol versus placebo for schizophrenia

Review

Claire Bronwen Joy, Clive E Adams, Stephen Lawrie

https://doi.org/10.1002/14651858.CD003082

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.